Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Divalproex sodium
Drug ID BADD_D00696
Description Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton.[A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.
Indications and Usage For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome.
Marketing Status Prescription; Discontinued
ATC Code N03AG01
DrugBank ID DB00313
KEGG ID D00304
MeSH ID D014635
PubChem ID 23663956
TTD Drug ID D03LGY
NDC Product Code 55111-530; 70518-1749; 65862-959; 0904-6615; 55111-529; 68084-782; 63187-742; 65162-755; 71610-032; 68788-7183; 71335-1883; 50090-4409; 68084-776; 57237-047; 64679-724; 51079-766; 29300-138; 55154-5633; 0615-8326; 70518-2527; 50090-3616; 55111-534; 71610-031; 29300-380; 70518-0312; 50090-2795; 68084-313; 68001-472; 68001-473; 63629-4278; 51655-365; 70518-0282; 0615-8237; 55154-2336; 71335-0008; 70518-2036; 70518-2626; 67296-1677; 0615-8329; 66064-1001; 29300-381; 70518-2665; 23639-0001; 0074-6114; 57237-048; 68180-265; 55111-532; 0832-7124; 55700-938; 68071-4102; 68001-106; 0904-6861; 68382-134; 70518-3055; 70518-0463; 55154-4759; 65862-594; 62756-797; 0074-7325; 70518-1759; 65841-639; 68382-133; 68382-032; 50268-258; 70518-2357; 71610-157; 70518-1558; 0074-7402; 16714-485; 65841-637; 70518-3183; 0074-6214; 51079-767; 68382-033; 50090-3416; 55700-939; 70518-2513; 55111-533; 0832-7123; 71610-249; 70518-1897; 71610-289; 0074-6215; 48433-125; 71610-205; 48433-126; 71610-311; 68382-106; 65862-402; 68180-260; 70518-3364; 70518-2003; 0904-6363; 65862-975; 68788-7177; 55154-4679; 71610-201; 63187-743; 68001-474; 0904-6364; 65841-638; 70518-1138; 62756-798; 63629-4698; 65841-634; 17856-0262; 65862-595; 68788-8145; 55154-7640; 68108-0234; 16714-484; 68084-415; 27241-115; 68180-261; 50090-4187; 0378-0472; 0904-6860; 55111-531; 70518-1781; 65977-0114; 68382-031; 65841-635; 67296-1635; 0832-7122; 70518-1456; 49452-2542; 0615-8377; 55154-7145; 0074-7327; 50090-4861; 0074-7401; 60687-211; 17349-0011; 68001-105; 50090-5843; 64679-725; 55111-875; 58118-0040; 50090-5783; 70518-2510; 68925-0005; 68788-8085; 71610-030; 68180-267; 70518-1758; 65162-757; 70518-1556; 62756-796; 47621-006; 0615-8328; 0378-0473; 70600-016; 70518-0374; 43353-547; 17856-0109; 0074-3826; 70518-2674; 57237-106; 29300-140; 49169-1028; 65841-636; 0615-8327; 68180-266; 50090-4737; 61919-648; 29300-139; 50090-2007; 55154-3552; 0615-8376; 65862-403; 0615-8330; 0074-7126; 50090-5842; 68084-310; 0074-6212
Synonyms Valproic Acid | 2-Propylpentanoic Acid | 2 Propylpentanoic Acid | Divalproex | Depakene | Convulsofin | Depakote | Dipropyl Acetate | Divalproex Sodium | Semisodium Valproate | Vupral | Valproic Acid, Sodium Salt (2:1) | Propylisopropylacetic Acid | Ergenyl | Magnesium Valproate | Valproate | Valproate Sodium | Sodium Valproate | Calcium Valproate | Valproate Calcium | Depakine
Chemical Information
Molecular Formula C16H31NaO4
CAS Registry Number 76584-70-8
SMILES CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 1A2P05177Not AvailableNot Available
HepatotoxicityCytochrome P450 2E1P05181Not AvailableNot Available
HepatotoxicityCytochrome P450 2C9P11712T19244Not Available
HepatotoxicityCytochrome P450 2A6P11509T06455Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nervousness19.06.02.003--Not Available
Nystagmus06.05.02.006; 17.02.02.006--
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.011--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Osteoarthritis15.01.04.001--Not Available
Otitis media11.01.05.004; 04.05.01.001--
Pain08.01.08.004--
Palpitations02.01.02.003--
Pancreatitis07.18.01.001--
Pancreatitis acute07.18.01.002--Not Available
Pancytopenia01.03.03.003--Not Available
Paraesthesia17.02.06.005--
Parkinsonism17.01.05.003--Not Available
Parotid gland enlargement07.06.03.001--Not Available
Personality disorder19.05.02.002--Not Available
Petechiae01.01.03.002; 24.07.06.004; 23.06.01.003--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Photophobia17.17.02.006; 06.01.01.004--
Photosensitivity reaction23.03.09.003--
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Pollakiuria20.02.02.007--
Polycystic ovaries21.11.01.006; 05.05.01.014--Not Available
Porphyria acute17.19.01.001; 14.14.01.002; 09.01.10.001; 03.08.01.002; 19.07.03.003--Not Available
Pruritus23.03.12.001--
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages